TTrialPathMatch Me to Trials
← Back to trials
RecruitingPrimary Biliary Cholangitis

Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis

Eligible age

18–75 yrs

Accepts

All genders

Locations

0 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The main objectives of the study were to assess the effects of fenofibrate on serum alkaline phosphatase, as a composite endpoint and on safety in participants with primary biliary cholangitis (PBC).

Sponsor: Xijing Hospital of Digestive Diseases

You may qualify if…

  • ✓ Must have provided written informed consent
  • ✓ Age 18-75 years;
  • ✓ BMI 17-28 kg/m2
  • ✓ Male or female with a diagnosis of PBC, by at least two of the following criteria:
  • ✓ 1. History of AP above ULN for at least six months;
  • ✓ 2. Positive AMA titers (\>1/40 on immunofluorescence or M2 positive by enzyme linked immunosorbent assay (ELISA) or positive PBC-specific antinuclear antibodies;
  • ✓ 3. Documented liver biopsy result consistent with PBC.
  • ✓ Diagnosis of compensated cirrhosis, as demonstrated by the presence of ≥ 1 of the following 4 diagnostic factor

You may not qualify if…

  • ✕ History or presence of other concomitant liver diseases.
  • ✕ ALT or AST \> 5×ULN, TBIL \> 3×ULN.
  • ✕ If female: known pregnancy, or has a positive urine pregnancy test (confirmed by a positive serum pregnancy test), or lactating.
  • ✕ Allergic to fenofibrate or ursodeoxycholic acid.
  • ✕ Taking hepatotoxic drugs (e.g., dapsone, erythromycin, fluconazole, ketoconazole, rifampicin) for more than 2 weeks within 6 months, and long-term hormonal users.
  • ✕ Recurrent variceal bleeding, poorly controlled hepatic encephalopathy or refractory ascites.
  • ✕ Patients with a history of severe cardiac, cerebrovascular, renal, respiratory disease or functional failure, and psychiatric disorders (including those due to alcohol and drug abuse).
  • ✕ Creatinine \>1.5×ULN and creatinine clearance \<60 ml/min.

Source: ClinicalTrials.gov · NCT05749822 · last updated 2026-01-08